In a new study co-authored by Curta researchers, the introduction of a new bioengineered human arterial conduit in the acute trauma care setting may result in cost savings to both trauma centers and insurers.
“Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible” by Velez et al., published in the Journal of Medical Economics on February 18, 2025, evaluates the financial implications of using acellular tissue-engineered vessels (TEVs) for repairing extremity arterial injuries when autologous vein grafts are unavailable.
Researchers developed a budget impact model to compare the costs associated with TEVs versus traditional synthetic grafts over three years. The analysis suggests that incorporating TEVs into clinical practice may be a cost-saving strategy, potentially leading to better patient outcomes and reduced long-term healthcare expenses.